Table 2

Effect of BrpA deficiency on susceptibility to cell envelope antimicrobialsa

StrainMIC and MBC (μg/ml) for each antimicrobial
Lipid II inhibitorsNon-lipid II inhibitorsCell membrane-disrupting agents
VanNisBacPend-CycChlSDSTri
MICMBCMICMBCMICMBCMICMBCMICMBCMICMBCMICMBCMICMBC
UA1590.751.2517.527.51001,6000.040.07530011,0001.5640606075
TW14D0.50110b15b50c1,4000.030.07525011,0001.53c3040b5070
  • a Van, vancomycin; Nis, nisin; Bac, bacitracin; Pen, penicillin G; d-Cyc, d-Cycloserine; Chl, chlorhexidine; SDS, sodium dodecyl sulfate; Tri, triclosan.

  • b Reduction in MIC and/or MBC of more than 1.5-fold compared to UA159.

  • c Reduction in MIC and/or MBC of more than 2-fold compared to UA159.